echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > APT: The role of glucagon-like peptide-1 receptor agonists in nonalcoholic steatohepatitis, obesity and diabetes

    APT: The role of glucagon-like peptide-1 receptor agonists in nonalcoholic steatohepatitis, obesity and diabetes

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation and inflammation without secondary causes and heavy alcohol consumption


    Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation and inflammation without secondary causes and heavy alcohol consumption



    Insulin resistance is a major component of the metabolic syndrome, an important feature of T2D and obesity, and a key causative factor in NASH


    nonalcoholic fatty liver

    These insights have led to the search for new potential treatments as our understanding of the pathophysiology of NASH continues to grow


    Objective: To review the research on GLP-1RAs related to NASH treatment


    Methods: PubMed was searched and the results were sorted


    Results: Large trials using GLP-1RAs in T2D demonstrated highly effective glucose lowering, weight loss, and, in some cases, reductions in cardiovascular events and improvements in hepatic transaminases


    Cardiovascular Event Statistics Pancreatic Cancer

    Figure 1 Overview of the physiological effects of the GLP-1 receptor agonist GLP-1RA (drug-specific)

    Figure 1 Overview of the physiological effects of the GLP-1 receptor agonist GLP-1RA (drug-specific)

    Table: Review of phase III international CVOTS using GLP-1RAs in patients with T2D and high cardiovascular risk

    Table: Review of phase III international CVOTS using GLP-1RAs in patients with T2D and high cardiovascular risk

    Conclusions: These studies support the use of GLP-1RAs to improve the underlying metabolic dysfunction observed in NASH and recommend further long-term phase III trials


    These studies support the use of GLP-1RAs to improve the underlying metabolic dysfunction observed in NASH and recommend further long-term phase III trials


    Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.